LAGUNA HILLS, Calif., Nov. 9, 2026 /PRNewswire/ -- LASEROPTEK America Corp., a provider of advanced dermatological laser technologies, welcomes the American Medical Association's (AMA) release of the 2027 Current Procedural Terminology (CPT^®) code set, which includes important revisions to the 96920–96922 family of codes used to report targeted UVB laser treatments.

Effective January 1, 2027, the revised parent descriptor for the CPT code 96920–96922 family says "Laser treatment, 308-312 nanometer wavelengths, for inflammatory or autoimmune skin diseases (eg psoriasis)." The descriptor uses laser technology-neutral language, consistent with the CPT Editorial Panel's determination that the codes are not intended to be limited by laser type so long as the laser delivers UVB laser light within the 308–312 nanometer wavelength range. The revised descriptor eliminates the potential for confusion regarding the applicability of the codes across different laser platforms and expands reportable treatment indications beyond psoriasis, supporting technology choice based on patient needs, clinical objectives, and practice requirements.

CPT Coding Clarity Across Laser Technologies

Advances in photonics engineering have expanded the range of technologies available for UVB phototherapy. Among these innovations, solid-state laser technology represents an important advancement in targeted UVB phototherapy, offering physicians an alternative laser architecture for delivering therapeutic UVB wavelengths and greater flexibility in selecting treatment systems to meet evolving clinical needs.

The revised CPT descriptors provide greater clarity regarding the applicability of the codes across laser platforms that deliver UVB light within the 308–312 nanometer range. This clarity supports an environment in which physicians can evaluate treatment systems based on clinical utility, reliability, operating economics, and individual practice requirements.

The revised CPT descriptors also refer to inflammatory or autoimmune skin diseases, with psoriasis as an example, reflecting the broader clinical applications of targeted UVB laser therapy.

Physicians remain responsible for correct coding, and coverage for any particular condition is determined by individual payers. CPT codes do not dictate payer coverage or reimbursement policy, and the inclusion of a service in the CPT code set is not an endorsement by the AMA of any particular device. Coverage and reimbursement remain subject to individual payer coverage policies, medical necessity requirements, and applicable payment determinations.

PALLAS and PALLAS Premium

LASEROPTEK's PALLAS and PALLAS Premium are U.S. FDA-cleared solid-state UVB laser systems designed to meet the clinical and operational needs of dermatology practices [PALLAS: K172639 & K191501, PALLAS Premium: K223588]. Utilizing proprietary solid-state laser technology, the PALLAS family offers targeted UVB laser systems operating at either 308 nm or 311 nm, both within the 308–312 nanometer range referenced in the revised CPT descriptors. The wavelength is selected by the purchaser at the time of ordering.

PALLAS systems are available through equipment purchase or fixed-term, fixed-cost monthly rental arrangements, allowing practices to establish a predictable equipment-cost structure.

With two system models designed to accommodate different treatment volumes, PALLAS and PALLAS Premium offer physicians the flexibility to select a platform suited to their clinical and operational needs.

Built on More Than Two Decades of Laser Innovation and Global Clinical Experience

With more than 26 years of experience developing and commercializing advanced medical laser technologies for dermatological applications, LASEROPTEK has established a global customer base for its PALLAS platform across Asia, the Middle East, and the United States. The company's extensive international clinical experience encompasses the treatment of a broad range of inflammatory and autoimmune skin diseases, including, but not limited to, psoriasis, vitiligo, and atopic dermatitis, providing a strong foundation for supporting U.S. physicians through clinical education, treatment protocol development, and practice integration.

Combined with the coding clarity provided by the 2027 CPT code set, LASEROPTEK believes its established global experience and solid-state laser technology position the company to support physicians offering targeted UVB laser therapy in the United States.

"At LASEROPTEK, we believe the true value of medical innovation is measured not only by technological advancement, but by its ability to improve patient care and make effective treatments more accessible. Our mission is to equip physicians with advanced, clinically versatile laser technologies that enable them to address a broader range of patient needs," said Christopher Dalton, Vice President of LASEROPTEK America.

Looking Ahead

LASEROPTEK is expanding its U.S. commercial outreach, technical service, and clinical education to empower dermatologists with greater choice in targeted UVB laser technology and help more patients access targeted UVB laser treatments.

Physician choice and patient access are central to LASEROPTEK's mission. By advancing laser technology and supporting clinical education, the company aims to give more physicians the tools to provide targeted UVB laser therapies to the patients who need it. 

About LASEROPTEK America Corp.:

Founded in 2024, LASEROPTEK America Corp. is the U.S. subsidiary of LASEROPTEK Co. Ltd., a global medical laser manufacturer specializing in advanced technologies for medical and aesthetic dermatology. Through commercial outreach, technical service, clinical research, and clinical education, LASEROPTEK America helps U.S. dermatology and medical aesthetic practices evaluate and adopt the company's advanced laser technologies. Its initiatives focus on expanding physician choice, expanding patient access to advanced laser therapies, and building lasting relationships with healthcare providers and researchers.
 

Established in 2000, LASEROPTEK Co. LTD. combines in-house research and development, proprietary laser engineering, and advanced manufacturing capabilities to develop clinically relevant dermatological laser systems. Serving aesthetic and medical practices worldwide, the company is committed to technological innovation, clinical performance, product reliability, and long-term customer support.

For additional information, visit www.laseroptek.com and www.pallaslaser.com.

CPT® is a registered trademark of the American Medical Association. The AMA does not endorse any particular device, and CPT codes do not dictate payer coverage or reimbursement policy. Physicians remain responsible for correct coding. Coverage and reimbursement are determined by applicable payer policies, medical necessity criteria, and other requirements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/laseroptek-welcomes-2027-cpt-code-descriptor-clarifications-for-targeted-uvb-laser-therapy-supporting-patient-care-and-physician-choice-302933894.html

SOURCE LASEROPTEK America Corp.